AstraZeneca is in the unique position to provide a selection of high-quality tool compounds to create valuable opportunities to explore disease biology in the preclinical setting. AstraZeneca desires proposals that link one or more of these compounds to the following therapeutic areas: respiratory disease, cardiovascular disease, renal disease, or diabetes.
AstraZeneca intends to make up to 5 awards from a total award pool of $50,000. Winning proposals could be selected to receive up to $50,000 in additional research funding.
This Theoretical Challenge requires only a written proposal.
Pharmaceutical R&D faces several significant challenges in terms of identifying drug targets that translate from basic science into clinical projects and then ultimately into medicines that make a difference to the lives of patients. For every medicine that is prescribed, there are many other drug candidates which do not reach the approval stage. Some of these molecules have been studied extensively and their behavior is well characterized in vitro and in vivo. The availability of high-quality tool compounds enables potential mechanisms of disease to be investigated that may provide novel insights into the biology of the disease and hopefully better translation into the clinic. AstraZeneca is seeking proposals that probe novel mechanisms for a subset of human disease, respiratory, cardiovascular, renal, and diabetes (see Challenge Details for more information).
This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker.
To receive an award, the Solvers will not have to transfer their exclusive IP rights to the Seeker. Instead, Solvers will grant to the Seeker a non-exclusive license to practice their solutions.
Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on August 1, 2018.
Late submissions will not be considered.
ABOUT THE SEEKER
AstraZeneca is a global, science-led, biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three main therapy areas – Oncology, Cardiovascular & Metabolic Diseases and Respiratory. AstraZeneca also is selectively active in the areas of autoimmunity, neuroscience and infection. As an innovation-driven research organization, AstraZeneca recognizes that great ideas come from many sources. Open innovation is an avenue by which ideas can be shared and AstraZeneca recently launched a pavilion to further its commitment to facilitate the advancement of pharmaceutical research.
What is a Theoretical-Licensing Challenge?
An InnoCentive Theoretical Challenge builds upon an idea but is not yet a proof of concept. A solution to a Theoretical Challenge will solidify the Solver's concept with detailed descriptions, specifications and requirements necessary to bringing a good idea closer to becoming an actual product or service.
This Challenge is a Theoretical-Licensing Challenge, meaning that the Seeker is requesting non-exclusive rights to use the winning solution. By contrast, Theoretical-IP Transfer means that Solvers must relinquish all rights to the Intellectual Property (IP) for which they are awarded. For these forms of a Theoretical Challenge, Solvers that do not win retain the rights to their solution after the evaluation period is complete. The Seeker retains no rights to any IP not awarded.